NCT Number: NCT07534462
The objective of this prospective observational study is to evaluate the effects of Impella 5.5 on biventricular function in adult patients with end-stage heart failure requiring temporary mechanical circulatory support. The study will assess changes in left and right ventricular global longitudinal strain and myocardial work, as well as additional echocardiographic and hemodynamic parameters. Measurements will be obtained at baseline prior to Impella implantation, immediately after device initiation, and during postoperative follow-up up to Day 14. This study involves collection of echocardiographic imaging and clinical data, including additional imaging performed for research purposes.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
This is a single-center, single-arm, prospective observational study designed to evaluate the effects of Impella 5.5 on left ventricular unloading and biventricular function in patients with end-stage heart failure requiring temporary mechanical circulatory support.
Echocardiographic assessments will be performed at three time points: prior to Impella implantation (baseline), immediately after device initiation intraoperatively, and during postoperative follow-up up to Day 14. Measurements will include left and right ventricular global longitudinal strain, myocardial work, and standard echocardiographic parameters such as left ventricular ejection fraction, ventricular volumes, and right ventricular functional indices.
Hemodynamic parameters, including arterial blood pressure, central venous pressure, pulmonary artery pressure, cardiac output, and mixed venous oxygen saturation, will also be collected. The vasoactive inotropic score will be calculated to evaluate changes in pharmacologic support.
This study is observational in nature and does not alter clinical management. Additional echocardiographic imaging may be obtained for research purposes in conjunction with standard of care procedures.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Echocardiographic imaging will be performed at baseline prior to Impella implantation, immediately after device initiation, and during postoperative follow-up up to Day 14 to assess biventricular function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Left ventricular global longitudinal strain will be measured using speckle-tracking echocardiography from transesophageal and transthoracic images. LV endocardial borders are manually traced, and strain is calculated as the average peak systolic longitudinal strain across left ventricular segments. Values are expressed as percentage. More negative values indicate better myocardial function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day14
Left ventricular myocardial work will be calculated using pressure-strain loop analysis derived from echocardiographic strain data combined with non-invasive blood pressure measurements using EchoPac software. Higher values indicate improved myocardial performance.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Right ventricular global longitudinal strain will be measured using speckle-tracking echocardiography from apical or transesophageal four-chamber views. RV free wall segments are analyzed and averaged to determine strain. Values are expressed as percentage. More negative values indicate better myocardial function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Left ventricular ejection fraction will be measured using three-dimensional echocardiographic imaging and automated quantification software. Higher values indicate better ventricular function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Left ventricular end-diastolic volume will be measured using three-dimensional echocardiography and represents the volume of blood in the left ventricle at end-diastole.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Left ventricular end-systolic volume will be measured using three-dimensional echocardiography and represents the volume of blood remaining in the ventricle after contraction.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Right ventricular ejection fraction will be assessed using three-dimensional echocardiographic imaging. Higher values indicate better ventricular function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Right ventricular end-diastolic volume will be measured using three-dimensional echocardiography.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Right ventricular end-systolic volume will be measured using three-dimensional echocardiography.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Tricuspid annular plane systolic excursion will be measured using M-mode echocardiography and reflects right ventricular longitudinal systolic function. Higher values indicate better right ventricular function.
Time frame: Baseline, immediately post-Impella initiation, and postoperative day up to Day 14
Right ventricular fractional area change is calculated as the percentage change in right ventricular area between end-diastole and end-systole. Higher values indicate better right ventricular function.
Contact information is provided by the study sponsor or research team.
Tammy Ortiz
CONTACT
YOSHIHISA MORITA
CONTACT
University of Rochester
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02592499
End-stage Heart Failure
Gothenburg, Sweden
View Trial DetailsNCT07633535
End-stage Heart Failure, Left Ventricular Assist Device
Antalya, Turkey (Türkiye)
View Trial DetailsNCT04641416
Cardiomyopathies, Cardiovascular Diseases
Vienna, Austria
View Trial DetailsNCT04768322
Cardiovascular Diseases, End-stage Heart Failure
Besançon, France
View Trial Details